XML 48 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
Loss before income tax - Additional Information (Details)
€ in Millions
 1 Months Ended 6 Months Ended
Jun. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2021
EUR (€)
Feb. 29, 2020
USD ($)
Dec. 31, 2019
USD ($)
Oct. 31, 2019
USD ($)
Oct. 31, 2018
USD ($)
milestone
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Jun. 30, 2023
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2017
EUR (€)
Disclosure Of Loss Before Income Tax [Line Items]                        
Revenue recognized from up-front payment as deferred consideration       $ 10,000,000                
Receipt on non refundable up-front payment upon reaching product regulatory milestone             $ 25,000,000          
Escalating milestone payments | milestone             6          
Pre-launch inventory recognized               $ 21,600,000   $ 22,400,000    
Manufacturing Commercialization Expenses                        
Disclosure Of Loss Before Income Tax [Line Items]                        
Pre-launch inventory recognized               (800,000) $ 1,600,000      
Grunenthal                        
Disclosure Of Loss Before Income Tax [Line Items]                        
Non-refundable upfront payment received           $ 15,000,000            
Milestone payment received         $ 2,500,000              
Percentage of patients to provide regulatory harmonization, cost efficiencies and streamlined timelines 20.00%                      
Non-refundable upfront payments receivable $ 17,500,000                      
Cumulative milestone payments reachable amount 1,000,000,000                      
Revenue recognized for right of use license of IP               0 0      
Grunenthal | Top of Range | Clinical, Manufacturing, Regulatory and Reimbursement Approval                        
Disclosure Of Loss Before Income Tax [Line Items]                        
Amount entitled to be received upon reaching product clinical and regulatory milestones and reimbursement targets are achieved $ 112,500,000                      
Tasly                        
Disclosure Of Loss Before Income Tax [Line Items]                        
Deferred consideration milestone consideration recognized             $ 20,000,000          
Revenue recognized from up-front payment as deferred consideration             $ 10,000,000          
Tasly | License                        
Disclosure Of Loss Before Income Tax [Line Items]                        
Revenue recognized from up-front payment as deferred consideration               0 0      
TiGenix NV                        
Disclosure Of Loss Before Income Tax [Line Items]                        
Royalty income               200,000 200,000      
TiGenix NV | License                        
Disclosure Of Loss Before Income Tax [Line Items]                        
Current contract liabilities                     $ 5,900,000 € 5.0
Non-current contract liabilities                     $ 5,900,000 € 5.0
Revenue from contracts with customers   $ 1,200,000 € 1.0                  
TiGenix NV | Top of Range | License                        
Disclosure Of Loss Before Income Tax [Line Items]                        
Revenue, remaining performance obligation, variable consideration amount | €     € 9.0                  
JCR Pharmaceuticals Co. Ltd                        
Disclosure Of Loss Before Income Tax [Line Items]                        
Royalties receivable under sales-based milestones               $ 3,200,000 $ 3,200,000